Fosrenol Related Published Studies
Well-designed clinical trials related to Fosrenol (Lanthanum Carbonate)
Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. [2007.11]
Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. [2007.02]
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. [2006.08]
Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. [2006.07]
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. [2006.03]
Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. [2006]
The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. [2005.12]
Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. [2005.06]
Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. [2005.04]
Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. [2005]
Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. [2004.09]
Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. [2003.07]
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. [2003.06]
Other research related to Fosrenol (Lanthanum Carbonate)
Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. [2008.10]
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. [2008.09]
Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians: A Multicenter Study. [2008.06.25]
[Radiographic characteristics of lanthanum carbonate absorption] [2008.04]
Lanthanum Carbonate Effectively Controls Serum Phosphate Without Affecting Serum Calcium Levels in Patients Undergoing Hemodialysis. [2008.02]
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. [2007.12]
Effects of Lanthanum Carbonate on the Absorption and Oral Bioavailability of Ciprofloxacin. [2007.10.03]
Lanthanum carbonate as a first-line phosphate binder: the "cons". [2007.07]
Lanthanum carbonate--a first line phosphate binder? [2007.07]
Systemic lanthanum is excreted in the bile of rats. [2007.06.15]
Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. [2007.04]
Lanthanum carbonate: time to abandon prejudices? [2007.02]
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. [2007.02]
The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. [2007.01]
Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients. [2007.01]
Lanthanum carbonate. [2006.12]
Lanthanum: a safe phosphate binder. [2006.05]
Lanthanum carbonate. [2006.02]
Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. [2005.09]
A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. [2005.05]
Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. [2005.05]
Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. [2005.02]
Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. [2005.02]
Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. [2005.02]
Blast from the past: the aluminum's ghost on the lanthanum salts. [2005]
Lanthanum carbonate: a new phosphate binder. [2004.07]
Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. [2004.07]
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. [2004]
Lanthanum carbonate (Shire). [2003.07]
Other possibly related research studies
Effects of efficient phosphate binding on bone in chronic renal failure rats. [2005]
The clinical management of hyperphosphatemia. [2005.05]
Improving phosphate-binder therapy as a way forward. [2004.03]
Phosphate binder usage in kidney failure patients. [2003.06]
[Management of hyperphosphoremia] [2003]
Hyperphosphataemia in renal failure: causes, consequences and current management. [2003]
Gateways to clinical trials. [2006.10]
Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. [2006.06]
Gateways to clinical trials. [2006.05]
Hyperphosphatemia and phosphate binders. [2005.11.15]
Gateways to clinical trials. [2005.10]
Control of hyperphosphatemia among patients with ESRD. [2005.11]
Gateways to clinical trials. [2005.07]
Gateways to clinical trials. [2005.05]
[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics] [2005]
Accumulation of metals and minerals from phosphate binders. [2005]
Gateways to clinical trials. [2004.12]
[New aspects in the management of renal osteodystrophy] [2004.10]
The therapeutic potential of novel phosphate binders. [2005.03]
Hyperphosphatemia in renal failure. [2005]
Gateways to clinical trials. [2004.10]
Improving outcomes in hyperphosphataemia. [2004.03]
Gateways to clinical trials. [2003.10]
Recent advances in nephrology. [2003.09]
Safety of new phosphate binders for chronic renal failure. [2003]
Gateways to clinical trials. [2003.09]
Gateways to clinical trials. [2003.07]
Gateways to clinical trials. [2003.06]
Gateways to clinical trials. [2003.05]
Recent advances in nephrology: highlights from the 35th annual meeting of the American society of nephrology. [2002.12]
A new era in phosphate binder therapy: what are the options? [2006.12]
[Phosphate binder up to date] [2007.05]
Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? [2007.03]
The therapeutic application of lanthanides. [2006.06]
Emerging drugs for hyperphosphatemia. [2007.09]
CKD-MBD: impact on management of kidney disease. [2007.12]
Preventive measures and new pharmacological approaches of calcium and phosphate disorders. [2008]
|
